With the new center, which spans 60,000 square feet, Avantor has doubled its previous laboratory and pilot plant capacity. Designed for collaborative work, the facility includes spaces for upstream and downstream process development, dedicated analytical testing labs, and a viral vector laboratory. An expanded pilot plant supports scale-up simulations, enabling rapid customization across the entire bioprocessing workflow, Avantor said.

Michael Stubblefield, CEO of the US-headquartered contract development and manufacturing organization (CDMO), commented: "Working side-by-side with customers in our network of innovation centers across the globe enables us to power science at every step to deliver life-changing therapies faster, and more cost effectively."

The Bridgewater Innovation Center allows Avantor to optimize and accelerate biomanufacturing processes at scale; resulting in faster problem solving, streamlined knowledge exchange, and strategic co-innovation.

In addition to enhancing both capacity and expertise to support customers' needs, the facility also supports Avantor's sustainability goals, reinforcing the company's commitment to environmental responsibility.